GRI Bio, Inc.

GRISEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1824293

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	—	$100.0K
Research and Development Expense	$3.8M	$3.2M	$242.0K	$5.2M	$3.7M
Operating Expenses	$8.2M	$11.4M	$2.2M	$9.3M	$4.9M
Operating Income (Loss)	-$8.2M	-$11.4M	-$2.2M	-$9.3M	-$4.8M
Other Nonoperating Income (Expense)	—	$250.0K	$0.00	$61.0K	$0.00
Income Tax Expense (Benefit)	$2.0K	—	—	—	—
Net Income (Loss) Attributable to Parent	-$8.2M	-$13.0M	-$3.2M	-$9.3M	-$4.8M
Earnings Per Share, Basic	-$1.5K	-$5.0K	-$24.95	-$1.42	-$1.07
Earnings Per Share, Diluted

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$5.7M	$3.0M	$383.0K	$8.3M	$955.0K
Assets, Current	$5.6M	$2.9M	$312.0K	$8.1M	$674.0K
Cash and Cash Equivalents, at Carrying Value	$5.0M	$1.8M	$9.0K	$3.7M	$109.0K
Liabilities	$1.7M	$2.7M	$2.0M	$2.5M	$2.4M
Liabilities, Current	$1.6M	$2.7M	$2.0M	$2.4M	$2.2M
Accounts Payable, Current	$897.0K	$1.4M	$1.3M	$918.0K	$1.2M
Stockholders' Equity Attributable to Parent	$259.0K	-$1.6M	-$4.8M	-$1.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$8.6M	-$9.0M	-$1.1M	-$8.3M	-$3.7M
Net Cash Provided by (Used in) Investing Activities	$0.00	-$8.0K	-$3.0K	-$3.8M	-$2.0K
Net Cash Provided by (Used in) Financing Activities	$11.8M	$10.8M	$1.0M	$15.7M	-$4.0K
Payments to Acquire Property, Plant, and Equipment	$0.00	$8.0K	$3.0K	—	$2.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)